2018 ESC Guidelines for the diagnosis and management of syncope
This guideline cites 4 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2018
- Source
- Brignole M, Moya A, et al. Eur Heart J. 2018;39(21):1883–1948.doi 10.1093/eurheartj/ehy037
The 2018 ESC syncope guideline is built around one idea: treat the mechanism, not the diagnosis. Pacing helps in reflex syncope only when asystole has actually been documented — a lesson learned the hard way from the unblinded early pacemaker trials — and drug therapy is reserved for young patients with a heavy symptom burden. The register's trials are grouped by that logic below.
Pharmacotherapy of reflex syncope2
- 2016POST-2Cardiology · Arrhythmia · Vasovagal syncopeIn 210 patients with recurrent vasovagal syncope, fludrocortisone did not significantly reduce the first recurrence of syncope over one year compared with placebo, although a benefit emerged once the dose had been stabilised.HR 0.6995% CI 0.46-1.03Read →
- 2006POSTCardiology · Arrhythmia · Vasovagal syncopeIn 208 patients with recurrent vasovagal syncope and a positive tilt test, metoprolol at the highest tolerated dose did not reduce the first recurrence of syncope over one year compared with placebo.HR 0.8995% CI 0.63-1.25Read →
Pacing: only when asystole is documented2
- 2012ISSUE-3Cardiology · Arrhythmia · Pacing for reflex syncopeIn 77 patients aged 40 years or older with recurrent reflex syncope and asystole documented by an implantable loop recorder, an active dual-chamber pacemaker reduced recurrence of syncope at 2 years compared with the same pacemaker programmed to sensing only.25% vs 57%Read →
- 2003VPS-IICardiology · Arrhythmia · Pacing for reflex syncopeIn 100 patients with recurrent severe vasovagal syncope who all received a dual-chamber pacemaker, active dual-chamber pacing did not significantly reduce recurrence of syncope within 6 months compared with the pacemaker programmed to sensing only.31% vs 40%Read →
Published since the guideline2
- 2021POST-4Cardiology · Arrhythmia · Vasovagal syncopeIn 133 patients with recurrent vasovagal syncope and no serious comorbidity, midodrine reduced the proportion of patients with at least one syncope episode over 12 months compared with placebo.RR 0.6995% CI 0.49-0.97Read →
- 2021BIOSync CLSCardiology · Arrhythmia · Pacing for reflex syncopeIn 127 patients aged 40 years or older with severe recurrent reflex syncope and tilt-induced asystole, a dual-chamber pacemaker with closed-loop stimulation reduced recurrence of syncope compared with the same pacemaker programmed off.HR 0.2395% CI 0.11-0.47Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 1999VPS-I
The unblinded pacing trial whose apparent benefit VPS-II later exposed as a placebo effect of surgery.
- 2004SYNPACE
Pacing versus sensing-only in tilt-positive syncope — neutral, reinforcing VPS-II.
- 2006ISSUE-2
The loop-recorder observational study that generated the mechanism-guided pacing hypothesis.
- 2006Physical counterpressure manoeuvres (PC-Trial)
Leg crossing and arm tensing reduce syncope recurrence — the first-line non-pharmacological therapy.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.